Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis Martha K Daddario1, Jennifer K Hagerman2, Michael E Klepser21Spectrum Health, Grand Rapids, Michigan; 2Ferris State University College of Pharmacy, Kalamazoo, Michigan, USAAbstract: Progressive obstructive lung disease is a characteristic component of cystic fibrosis (CF). It is the pulmonary manifestations, including obstruction and endobronchial infection, which directly contribute to the premature mortality of patients affected with CF. Due to the devastating effects on the pulmonary system, interest abounds in ways to improve antimicrobial delivery to the lungs and to impact clinical patient outcomes positively, whilst minimizing systemic toxicities. Recently, aztreonam lysine for inhalation solution, a new monobactam formulation, was approved by the US Food and Drug Administration for use in a subgroup of CF patients with Pseudomonas aeruginosa to improve respiratory symptoms. The purpose of this review is to present a summary of relevant pharmacologic, microbiologic, and clinical data related to the use of aztreonam lysine for inhalation in patients with CF.Keywords: aztreonam, cystic fibrosis, inhaled, aerosolized, antibiotic, Pseudomonas aeruginosa